BB
ESPR

BB Biotech’s Esperion Therapeutics ESPR Stock Holding History

BB Biotech’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$141M Buy
3,522,964
+130,000
+4% +$5.83M 3.56% 10
2018
Q4 		$156M Buy
3,392,964
+110,000
+3% +$5.3M 5% 5
2018
Q3 		$146M Buy
3,282,964
+100,000
+3% +$4.59M 3.85% 11
2018
Q2 		$125M Buy
3,182,964
+770,000
+32% +$38.9M 3.6% 12
2018
Q1 		$175M Buy
2,412,964
+50,000
+2% +$3.67M 4.82% 9
2017
Q4 		$156M Buy
2,362,964
+265,000
+13% +$14.3M 4.38% 11
2017
Q3 		$105M Buy
2,097,964
+584,422
+39% +$28.2M 2.91% 13
2017
Q2 		$70M Buy
1,513,542
+105,000
+7% +$3.86M 2.14% 15
2017
Q1 		$49.7M Buy
1,408,542
+100,000
+8% +$2.29M 1.63% 16
2016
Q4 		$16.4M Hold
1,308,542
– – 0.61% 24
2016
Q3 		$18.1M Buy
1,308,542
+300,000
+30% +$3.4M 0.64% 23
2016
Q2 		$9.96M Hold
1,008,542
– – 0.39% 27
2016
Q1 		$17.1M Buy
1,008,542
+100,000
+11% +$1.61M 0.68% 22
2015
Q4 		$20.2M Hold
908,542
– – 0.57% 26
2015
Q3 		$21.4M Buy
+908,542
New +$57M 0.68% 25

Other funds holding ESPR

MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BB Biotech's ESPR Position: Q1 2019 in Review

BB Biotech increased its Esperion Therapeutics (ESPR) stake by 3.8% in Q1 2019, buying an estimated $5.83M and bringing the position to 3,522,964 shares worth $141M. The position accounts for 3.56% of the portfolio, ranked #10.

BB Biotech first reported a position in ESPR in Q3 2015 and has held it in 15 quarters since. The position peaked at $175M in Q1 2018. 163 funds tracked by Wall St. Rank hold ESPR as of Q1 2019.

  • BB Biotech held 3,522,964 shares of Esperion Therapeutics worth $141M as of Q1 2019.
  • BB Biotech bought 130,000 Esperion Therapeutics shares in Q1 2019, an estimated $5.83M.
  • Esperion Therapeutics made up 3.56% of BB Biotech's portfolio in Q1 2019, its #10 holding.
  • BB Biotech first reported a position in Esperion Therapeutics in Q3 2015 and has held it in 15 quarters since.
  • BB Biotech's Esperion Therapeutics position peaked at $175M in Q1 2018.
  • 163 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.